GSK plc (GSK) KPIs and segments
Close on Nov 18, 2026Market cap $104.82BP/E 13.2Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của GSK · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của GSK: 55 chỉ số vận hành, trong đó có Commercial Operations Total Turnover, U.S. Rebates, Allowances & Returns Gross-to-Net và Top 3 U.S. Pharmaceutical Wholesalers, lấy từ 113 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Commercial Operations Total Turnover4 | 8,887.00 | 8,409.00 | 7,629.00 | 8,618.00 | 8,547.00 | 7,986.00 | 7,516.00 | 8,106.00 | 8,012.00 | 7,884.00 | 7,362.00 | 8,052.00 | |
Commercial Operations Turnover — CER YoY Growth(%) | 5.0% | 5.0% | 5.0% | 8.0% | 8.0% | 6.0% | 4.0% | 4.0% | 2.0% | 13.0% | 13.0% | 15.0% | |
Commercial Turnover — U.S. | 4,931.00 | 4,308.00 | 3,737.00 | 4,443.00 | 4,549.00 | 4,115.00 | 3,752.00 | 4,317.00 | 4,321.00 | 4,147.00 | 3,589.00 | 4,380.00 | |
Commercial Turnover — Europe | 1,928.00 | 2,042.00 | 2,083.00 | 2,067.00 | 1,878.00 | 1,839.00 | 1,749.00 | 1,754.00 | 1,618.00 | 1,672.00 | 1,621.00 | 1,657.00 | |
Commercial Turnover — International | 2,028.00 | 2,059.00 | 1,809.00 | 2,108.00 | 2,120.00 | 2,032.00 | 2,015.00 | 2,035.00 | 2,073.00 | 2,065.00 | 2,152.00 | 2,015.00 | |
Specialty Medicines Total Turnover7 | 3,877.00 | 3,782.00 | 3,226.00 | 3,805.00 | 3,409.00 | 3,327.00 | 2,933.00 | 3,298.00 | 2,966.00 | 3,024.00 | 2,522.00 | 2,893.00 | |
Specialty Medicines Total Turnover — Constant Exchange Rate (CER) YoY Growth(%) | 15.0% | 14.0% | 14.0% | 18.0% | 16.0% | 15.0% | 17.0% | 17.0% | 19.0% | 22.0% | 17.0% | 12.0% | |
Specialty Medicines Total Turnover — U.S. | 2,674.00 | 2,591.00 | 2,089.00 | 2,684.00 | 2,316.00 | 2,259.00 | 1,922.00 | 2,330.00 | 1,991.00 | 2,079.00 | 1,595.00 | 2,021.00 | |
Specialty Medicines Total Turnover — Europe | 726.00 | 725.00 | 701.00 | 730.00 | 667.00 | 649.00 | 619.00 | 615.00 | 590.00 | 606.00 | 571.00 | 571.00 | |
Specialty Medicines Total Turnover — International | 477.00 | 466.00 | 436.00 | 391.00 | 426.00 | 419.00 | 392.00 | 353.00 | 385.00 | 339.00 | 356.00 | 301.00 | |
HIV Portfolio Total (ViiV Healthcare)6 | 2,116.00 | 2,078.00 | 1,824.00 | 2,149.00 | 1,944.00 | 1,880.00 | 1,714.00 | 1,969.00 | 1,750.00 | 1,757.00 | 1,613.00 | 1,773.00 | |
HIV Portfolio Total (ViiV Healthcare) — Constant Exchange Rate (CER) YoY Growth(%) | 10.0% | 10.0% | 10.0% | 11.0% | 12.0% | 12.0% | 7.0% | 14.0% | 12.0% | 13.0% | 14.0% | 10.0% | |
HIV Portfolio Total (ViiV Healthcare) — U.S. | 1,524.00 | 1,459.00 | 1,220.00 | 1,545.00 | 1,346.00 | 1,288.00 | 1,133.00 | 1,398.00 | 1,172.00 | 1,191.00 | 1,031.00 | 1,222.00 | |
HIV Portfolio Total (ViiV Healthcare) — Europe | 399.00 | 407.00 | 399.00 | 425.00 | 380.00 | 380.00 | 373.00 | 387.00 | 363.00 | 382.00 | 364.00 | 374.00 | |
HIV Portfolio Total (ViiV Healthcare) — International | 193.00 | 212.00 | 205.00 | 179.00 | 218.00 | 212.00 | 208.00 | 184.00 | 215.00 | 184.00 | 218.00 | 177.00 | |
Dolutegravir Franchise (Oral 2-Drug & 3-Drug Regimens)8 | 1,445.00 | 1,441.00 | 1,295.00 | 1,556.00 | 1,418.00 | 1,386.00 | 1,288.00 | 1,516.00 | 1,388.00 | 1,391.00 | 1,304.00 | 1,445.00 | |
Dolutegravir Franchise (Oral 2-Drug & 3-Drug Regimens) — Constant Exchange Rate (CER) YoY Growth(%) | 3.0% | 3.0% | 4.0% | 4.0% | 3.0% | 4.0% | 8.0% | 6.0% | 7.0% | 6.0% | 2.0% | ||
Dolutegravir Franchise (Oral 2-Drug & 3-Drug Regimens) — U.S. | 946.00 | 907.00 | 769.00 | 1,031.00 | 895.00 | 868.00 | 773.00 | 1,016.00 | 867.00 | 881.00 | 772.00 | 946.00 | |
Dolutegravir Franchise (Oral 2-Drug & 3-Drug Regimens) — Europe | 329.00 | 342.00 | 340.00 | 363.00 | 325.00 | 325.00 | 323.00 | 335.00 | 318.00 | 339.00 | 324.00 | 333.00 | |
Dolutegravir Franchise (Oral 2-Drug & 3-Drug Regimens) — International | 170.00 | 192.00 | 186.00 | 162.00 | 198.00 | 193.00 | 192.00 | 165.00 | 203.00 | 171.00 | 208.00 | 166.00 | |
Dovato (dolutegravir/lamivudine)4 | 754.00 | 749.00 | 666.00 | 758.00 | 695.00 | 655.00 | 570.00 | 638.00 | 567.00 | 551.00 | 483.00 | 516.00 | |
Tivicay (dolutegravir)4 | 319.00 | 318.00 | 311.00 | 346.00 | 330.00 | 333.00 | 314.00 | 343.00 | 335.00 | 318.00 | 354.00 | 349.00 | |
Triumeq (dolutegravir/abacavir/lamivudine)4 | 201.00 | 204.00 | 172.00 | 269.00 | 236.00 | 240.00 | 246.00 | 346.00 | 323.00 | 346.00 | 310.00 | 403.00 | |
Juluca (dolutegravir/rilpivirine)4 | 171.00 | 170.00 | 146.00 | 183.00 | 157.00 | 158.00 | 158.00 | 189.00 | 163.00 | 176.00 | 157.00 | 177.00 | |
Long-Acting Injectable HIV Regimens (Treatment & PrEP)6 | 621.00 | 593.00 | 488.00 | ||||||||||
Long-Acting Injectable HIV Regimens (Treatment & PrEP) — Constant Exchange Rate (CER) YoY Growth(%) | 31.0% | 35.0% | 34.0% | ||||||||||
Long-Acting Injectable HIV Regimens (Treatment & PrEP) — U.S. | 538.00 | 514.00 | 417.00 | ||||||||||
Long-Acting Injectable HIV Regimens (Treatment & PrEP) — Europe | 63.00 | 61.00 | 56.00 | ||||||||||
Long-Acting Injectable HIV Regimens (Treatment & PrEP) — International | 20.00 | 18.00 | 15.00 | ||||||||||
Cabenuva / Vocabria + Rekambys (Long-Acting HIV Treatment)4 | 478.00 | 453.00 | 368.00 | 410.00 | 357.00 | 341.00 | 294.00 | 310.00 | 245.00 | 245.00 | 213.00 | 223.00 | |
Apretude (cabotegravir Long-Acting HIV PrEP)3 | 143.00 | 140.00 | 120.00 | 129.00 | 120.00 | 101.00 | 89.00 | 84.00 | 69.00 | 72.00 | 54.00 | 52.00 | |
Respiratory, Immunology & Inflammation (RI&I)7 | 1,139.00 | 1,135.00 | 890.00 | 1,089.00 | 954.00 | 963.00 | |||||||
Respiratory, Immunology & Inflammation (RI&I) — Constant Exchange Rate (CER) YoY Growth(%) | 21.0% | 19.0% | 16.0% | 21.0% | 15.0% | 10.0% | |||||||
Respiratory, Immunology & Inflammation (RI&I) — U.S. | 758.00 | 772.00 | 534.00 | 752.00 | 621.00 | 635.00 | |||||||
Respiratory, Immunology & Inflammation (RI&I) — Europe | 173.00 | 170.00 | 176.00 | 169.00 | 165.00 | 154.00 | |||||||
Respiratory, Immunology & Inflammation (RI&I) — International | 208.00 | 193.00 | 180.00 | 168.00 | 168.00 | 174.00 | |||||||
Nucala (mepolizumab — IL-5 Biologic)4 | 582.00 | 610.00 | 484.00 | 567.00 | 499.00 | 498.00 | 444.00 | 484.00 | 444.00 | 482.00 | 374.00 | 471.00 | |
Benlysta (belimumab — SLE & Lupus Nephritis)4 | 520.00 | 498.00 | 384.00 | 516.00 | 447.00 | 451.00 | 359.00 | 423.00 | 389.00 | 418.00 | 260.00 | 389.00 | |
Exdensur (depemokimab — Ultra-Long-Acting Anti-IL-5)3 | 27.00 | 18.00 | 11.00 | ||||||||||
Oncology Portfolio Total8 | 622.00 | 569.00 | 512.00 | 567.00 | 511.00 | 484.00 | 415.00 | 408.00 | 373.00 | 356.00 | 273.00 | 244.00 | |
Oncology Portfolio Total — Constant Exchange Rate (CER) YoY Growth(%) | 23.0% | 17.0% | 28.0% | 42.0% | 39.0% | 42.0% | 53.0% | 72.0% | 94.0% | 62.0% | |||
Oncology Portfolio Total — U.S. | 392.00 | 360.00 | 335.00 | 387.00 | 349.00 | 336.00 | 292.00 | 299.00 | 264.00 | 251.00 | 186.00 | 163.00 | |
Oncology Portfolio Total — Europe | 154.00 | 148.00 | 126.00 | 136.00 | 122.00 | 115.00 | 96.00 | 88.00 | 88.00 | 86.00 | 75.00 | 70.00 | |
Oncology Portfolio Total — International | 76.00 | 61.00 | 51.00 | 44.00 | 40.00 | 33.00 | 27.00 | 21.00 | 21.00 | 19.00 | 12.00 | 11.00 | |
Jemperli (dostarlimab — PD-1 Immuno-Oncology)4 | 273.00 | 248.00 | 232.00 | 261.00 | 230.00 | 196.00 | 174.00 | 149.00 | 130.00 | 108.00 | 80.00 | 60.00 | |
Ojjaara / Omjjara (momelotinib — Myelofibrosis)4 | 195.00 | 187.00 | 144.00 | 158.00 | 146.00 | 138.00 | 112.00 | 118.00 | 98.00 | 85.00 | 52.00 | 29.00 | |
Zejula (niraparib — PARP Inhibitor)4 | 104.00 | 101.00 | 114.00 | 138.00 | 137.00 | 151.00 | 131.00 | 143.00 | 144.00 | 165.00 | 141.00 | 152.00 | |
Blenrep (belantamab mafodotin — BCMA ADC)3 | 50.00 | 36.00 | 23.00 | 13.00 | 4.00 | 1.00 | 3.00 | -2.00 | 6.00 | ||||
Vaccines Total Turnover9 | 2,583.00 | 2,284.00 | 2,149.00 | 2,293.00 | 2,678.00 | 2,091.00 | 2,095.00 | 2,212.00 | 2,650.00 | 1,999.00 | 2,277.00 | 2,583.00 | |
Vaccines Total Turnover — Constant Exchange Rate (CER) YoY Growth(%) | -2.0% | 8.0% | 4.0% | 4.0% | 2.0% | 9.0% | -6.0% | -12.0% | -15.0% | 1.0% | 16.0% | 29.0% | |
Vaccines Total Turnover — U.S. | 1,266.00 | 779.00 | 815.00 | 782.00 | 1,264.00 | 716.00 | 888.00 | 985.00 | 1,458.00 | 765.00 | 1,078.00 | 1,380.00 | |
Vaccines Total Turnover — Europe | 735.00 | 818.00 | 857.00 | 832.00 | 725.00 | 705.00 | 615.00 | 618.00 | 522.00 | 537.00 | 509.00 | 545.00 | |
Vaccines Total Turnover — International | 582.00 | 687.00 | 477.00 | 679.00 | 689.00 | 670.00 | 592.00 | 609.00 | 670.00 | 697.00 | 690.00 | 658.00 | |
Shingrix (Recombinant Zoster / Shingles Vaccine)4 | 780.00 | 888.00 | 1,026.00 | 1,008.00 | 830.00 | 853.00 | 867.00 | 848.00 | 739.00 | 832.00 | 945.00 | 908.00 | |
Meningitis Vaccines Total7 | 599.00 | 462.00 | 335.00 | 313.00 | 541.00 | 379.00 | 350.00 | 295.00 | 520.00 | 323.00 | 299.00 | 273.00 | |
Meningitis Vaccines Total — Constant Exchange Rate (CER) YoY Growth(%) | 12.0% | 21.0% | -3.0% | 6.0% | 5.0% | 22.0% | 20.0% | 12.0% | 22.0% | 24.0% | 11.0% | 26.0% | |
Meningitis Vaccines Total — U.S. | 358.00 | 156.00 | 105.00 | 87.00 | 316.00 | 144.00 | 122.00 | 82.00 | 316.00 | 143.00 | 121.00 | 99.00 | |
Meningitis Vaccines Total — Europe | 144.00 | 173.00 | 156.00 | 154.00 | 154.00 | 157.00 | 138.00 | 144.00 | 122.00 | 116.00 | 101.00 | 104.00 | |
Meningitis Vaccines Total — International | 97.00 | 133.00 | 74.00 | 72.00 | 71.00 | 78.00 | 90.00 | 69.00 | 82.00 | 64.00 | 77.00 | 70.00 | |
Bexsero (Meningitis B Vaccine)4 | 378.00 | 331.00 | 263.00 | 250.00 | 367.00 | 282.00 | 251.00 | 227.00 | 334.00 | 232.00 | 217.00 | 171.00 | |
Menveo (MenACWY Conjugate Vaccine)4 | 189.00 | 98.00 | 65.00 | 53.00 | 168.00 | 92.00 | 89.00 | 50.00 | 173.00 | 84.00 | 80.00 | 87.00 | |
Penmenvy (Pentavalent MenABCWY Vaccine)1 | 30.00 | 11.00 | 6.00 | 3.00 | 5.00 | ||||||||
Arexvy (RSV Older Adults Vaccine)3 | 195.00 | 192.00 | 65.00 | 198.00 | 251.00 | 66.00 | 78.00 | 158.00 | 188.00 | 62.00 | 182.00 | 529.00 | |
Fluarix / FluLaval (Seasonal Influenza Vaccines)1 | 177.00 | 11.00 | 10.00 | 80.00 | 216.00 | 6.00 | 1.00 | 105.00 | 283.00 | 7.00 | 13.00 | 95.00 | |
Established / Paediatric & Adult Vaccines Total8 | 832.00 | 731.00 | 713.00 | 694.00 | 840.00 | 787.00 | 799.00 | 806.00 | 920.00 | 775.00 | 838.00 | 771.00 | |
General Medicines Total Turnover5 | 2,427.00 | 2,343.00 | 2,254.00 | 2,520.00 | 2,460.00 | 2,568.00 | 2,488.00 | 2,607.00 | 2,396.00 | 2,861.00 | 2,564.00 | 2,576.00 | |
General Medicines Total Turnover — U.S. | 991.00 | 938.00 | 833.00 | 977.00 | 969.00 | 1,140.00 | 942.00 | 1,012.00 | 872.00 | 1,303.00 | 916.00 | 979.00 | |
General Medicines Total Turnover — Europe | 467.00 | 499.00 | 525.00 | 505.00 | 486.00 | 485.00 | 515.00 | 522.00 | 506.00 | 529.00 | 541.00 | 541.00 | |
General Medicines Total Turnover — International | 969.00 | 906.00 | 896.00 | 1,038.00 | 1,005.00 | 943.00 | 1,031.00 | 1,073.00 | 1,018.00 | 1,029.00 | 1,107.00 | 1,056.00 | |
General Medicines — Inhaled Respiratory Portfolio11 | 1,708.00 | 1,679.00 | 1,594.00 | 1,785.00 | 1,702.00 | 1,871.00 | 1,710.00 | 1,806.00 | 1,617.00 | 2,065.00 | 1,725.00 | 1,746.00 | |
General Medicines — Inhaled Respiratory Portfolio — Constant Exchange Rate (CER) YoY Growth(%) | 1.0% | -10.0% | -4.0% | 1.0% | 7.0% | -5.0% | 1.0% | 7.0% | 11.0% | 18.0% | 2.0% | 9.0% | |
General Medicines — Inhaled Respiratory Portfolio — U.S. | 946.00 | 896.00 | 792.00 | 930.00 | 918.00 | 1,081.00 | 887.00 | 957.00 | 820.00 | 1,229.00 | 863.00 | 913.00 | |
General Medicines — Inhaled Respiratory Portfolio — Europe | 316.00 | 338.00 | 358.00 | 357.00 | 339.00 | 341.00 | 357.00 | 368.00 | 338.00 | 356.00 | 361.00 | 362.00 | |
General Medicines — Inhaled Respiratory Portfolio — International | 446.00 | 445.00 | 444.00 | 498.00 | 445.00 | 449.00 | 466.00 | 481.00 | 459.00 | 480.00 | 501.00 | 471.00 | |
Trelegy Ellipta (ICS/LAMA/LABA Single-Inhaler Triple Therapy)3 | 787.00 | 775.00 | 646.00 | 740.00 | 736.00 | 835.00 | 675.00 | 669.00 | 600.00 | 842.00 | 591.00 | 589.00 | |
Relvar / Breo Ellipta (ICS/LABA)4 | 221.00 | 231.00 | 230.00 | 229.00 | 256.00 | 267.00 | 265.00 | 275.00 | 241.00 | 281.00 | 270.00 | 302.00 | |
Seretide / Advair (salmeterol/fluticasone)4 | 191.00 | 195.00 | 188.00 | 243.00 | 199.00 | 200.00 | 216.00 | 259.00 | 218.00 | 298.00 | 282.00 | 276.00 | |
Ventolin (salbutamol Rescue Inhaler)4 | 181.00 | 130.00 | 144.00 | 196.00 | 156.00 | 166.00 | 185.00 | 170.00 | 176.00 | 188.00 | 168.00 | 198.00 | |
Anoro Ellipta (UMEC/VI LAMA/LABA)4 | 138.00 | 139.00 | 128.00 | 132.00 | 137.00 | 146.00 | 127.00 | 147.00 | 146.00 | 160.00 | 119.00 | 155.00 | |
Flixotide / Flovent (fluticasone propionate)4 | 73.00 | 90.00 | 128.00 | 113.00 | 98.00 | 111.00 | 99.00 | 143.00 | 113.00 | 132.00 | 139.00 | 100.00 | |
Other Inhaled Respiratory Medicines4 | 117.00 | 119.00 | 130.00 | 132.00 | 120.00 | 146.00 | 143.00 | 143.00 | 123.00 | 164.00 | 156.00 | 27.00 | |
Other General Medicines (Anti-Infectives, CNS, Urology & Legacy Brands)4 | 719.00 | 664.00 | 660.00 | 735.00 | 758.00 | 697.00 | 778.00 | 801.00 | 779.00 | 796.00 | 839.00 | 830.00 | |
Medicines & Vaccines in Clinical Development (Phase I–III / Registration)3 | 62 | 62 | 57 | 58 | 62 | 66 | 70 | 71 | |||||
Phase III / Registration Pipeline Assets3 | 21 | 19 | 16 | 17 | 16 | 16 | 18 | 19 | 18 | 18 | 18 | 18 | |
Phase III / Registration — Respiratory, Immunology & Inflammation (RI&I) | 5 | 4 | 6 | 6 | 6 | 6 | |||||||
Phase III / Registration — Oncology | 8 | 8 | 5 | 5 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | |
Phase III / Registration — Infectious Diseases & Vaccines | 7 | 6 | 5 | 6 | 6 | 6 | 7 | 8 | 7 | 7 | 7 | 7 | |
Phase II Pipeline Assets3 | 13 | 15 | 17 | 18 | 20 | 25 | 26 | 27 | 29 | 32 | 33 | 30 | |
Phase I Pipeline Assets3 | 28 | 28 | 24 | 23 | 26 | 25 | 26 | 25 | 20 | 20 | 21 | 23 | |
Total Clinical Development Projects (Including Lifecycle Indications) | 97 | 92 | 76 | 79 | 80 | 84 | 91 | 90 | 88 | 91 | 91 | 89 | |
Shingles Target Adult Population (Aged 50+)4 | 908,281,022 | 908,281,022 | 908,281,022 | 908,281,022 | 908,281,022 | 908,281,022 | 908,281,022 | 908,281,022 | 912,156,691 | 912,156,691 | 912,156,691 | 808,083,000 | |
Shingles Immunocompromised / At-Risk Population (Aged 18–49)4 | 910,856,971 | 910,856,971 | 910,856,971 | 910,856,971 | 910,856,971 | 910,856,971 | 910,856,971 | 910,856,971 | 911,086,540 | 911,086,540 | 911,086,540 | 952,578,000 | |
RSV Older Adults Target Population (Aged 65+)4 | 276,442,842 | 276,442,842 | 276,442,842 | 276,442,842 | 276,442,842 | 276,442,842 | 276,442,842 | 276,442,842 | 444,284,513 | 444,284,513 | 444,284,513 | 354,632,000 | |
RSV Adults Target Population (Aged 60+)4 | 366,132,158 | 366,132,158 | 366,132,158 | 366,132,158 | 366,132,158 | 366,132,158 | 366,132,158 | 366,132,158 | 608,598,792 | 608,598,792 | 608,598,792 | 474,359,000 | |
Seasonal Influenza Vaccine-Eligible Population (Aged 6 Months+)4 | 2,185,261,381 | 2,185,261,381 | 2,185,261,381 | 2,185,261,381 | 2,185,261,381 | 2,185,261,381 | 2,185,261,381 | 2,185,261,381 | 2,220,349,698 | 2,220,349,698 | 2,220,349,698 | 2,220,349,698 | |
Meningitis Infant Target Cohort2 | 37,401,137 | 37,401,137 | 37,401,137 | 37,401,137 | 37,401,137 | 37,401,137 | 37,401,137 | 37,401,137 | 46,205,287 | 46,205,287 | 46,205,287 | 46,205,287 | |
Meningitis Adolescent Target Cohort2 | 93,506,663 | 93,506,663 | 93,506,663 | 93,506,663 | 93,506,663 | 93,506,663 | 93,506,663 | 93,506,663 | 93,756,170 | 93,756,170 | 93,756,170 | 93,756,170 | |
Pneumococcal Paediatric Target Cohort4 | 374,514,156 | 374,514,156 | 374,514,156 | 374,514,156 | 374,514,156 | 374,514,156 | 374,514,156 | 374,514,156 | 407,164,902 | 407,164,902 | 407,164,902 | 407,164,902 | |
Pneumococcal Older Adult Target Population4 | 1,819,137,993 | 1,819,137,993 | 1,819,137,993 | 1,819,137,993 | 1,819,137,993 | 1,819,137,993 | 1,819,137,993 | 1,819,137,993 | 1,823,243,231 | 1,823,243,231 | 1,823,243,231 | 1,823,243,231 | |
HIV Prevalent People Living with HIV (Key Tracked Markets)6 | 2,058,000 | 2,756,000 | 2,756,000 | 2,756,000 | 2,058,000 | 2,756,000 | 2,756,000 | 2,756,000 | 2,163,000 | 2,756,000 | 2,756,000 | 2,756,000 | |
HIV Prevalent People Living with HIV (Key Tracked Markets) — U.S. | 1,200,000 | 1,793,000 | 1,793,000 | 1,793,000 | 1,200,000 | 1,793,000 | 1,793,000 | 1,793,000 | 1,200,000 | 1,793,000 | 1,793,000 | 1,793,000 | |
HIV Prevalent People Living with HIV (Key Tracked Markets) — EU5 (France, Germany, Italy, Spain, UK) | 820,000 | 911,000 | 911,000 | 911,000 | 820,000 | 911,000 | 911,000 | 911,000 | 911,000 | 911,000 | 911,000 | 911,000 | |
HIV Prevalent People Living with HIV (Key Tracked Markets) — Japan | 38,000 | 52,000 | 52,000 | 52,000 | 38,000 | 52,000 | 52,000 | 52,000 | 52,000 | 52,000 | 52,000 | 52,000 | |
HIV Diagnosed Patient Population3 | 1,854,000 | 2,247,000 | 2,247,000 | 2,247,000 | 1,854,000 | 2,247,000 | 2,247,000 | 2,247,000 | 1,857,000 | 2,247,000 | 2,247,000 | 2,247,000 | |
HIV Antiretroviral-Treated (ART) Patient Population3 | 1,698,000 | 1,868,000 | 1,868,000 | 1,868,000 | 1,698,000 | 1,868,000 | 1,868,000 | 1,868,000 | 1,672,000 | 1,868,000 | 1,868,000 | 1,868,000 | |
HIV Treatment-Naïve Patient Cohort3 | 49,000 | 55,500 | 55,500 | 55,500 | 49,000 | 55,500 | 55,500 | 55,500 | 50,500 | 55,500 | 55,500 | 55,500 | |
Chronic Hepatitis B (CHB) Prevalent Population (Bepirovirsen Target)6 | 60,693,143 | 60,693,143 | 60,693,143 | 60,693,143 | 60,693,143 | 60,693,143 | 60,693,143 | 60,693,143 | 60,693,143 | 60,693,143 | 60,693,143 | 60,890,405 | |
Severe Asthma — Diagnosed Patient Population7 | 63,626,238 | 63,626,238 | 63,626,238 | 63,626,238 | 63,647,799 | 63,647,799 | 63,647,799 | 63,647,799 | |||||
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Prevalent Patients5 | 14,446,806 | 14,446,806 | 14,446,806 | 14,446,806 | 14,410,388 | 14,410,388 | 14,410,388 | 14,410,388 | 15,241,723 | 15,241,723 | 15,241,723 | 15,241,723 | |
Hypereosinophilic Syndrome (HES) Diagnosed Patients7 | 15,223 | 15,223 | 15,223 | 15,223 | 15,223 | 15,223 | 15,223 | 15,223 | |||||
Uncomplicated Urinary Tract Infection (uUTI) Annual Treated Episodes (Blujepa Target)4 | 33,133,011 | 33,133,011 | 33,133,011 | 33,133,011 | 33,133,011 | 33,133,011 | 33,133,011 | 33,133,011 | 33,133,011 | 33,133,011 | 33,133,011 | 33,133,011 | |
Multiple Myeloma First-Line Drug-Treated Patients (Blenrep Target)4 | 88,810 | 88,810 | 88,810 | 88,810 | 88,810 | 88,810 | 88,810 | 87,902 | 102,770 | 102,770 | 102,770 | 102,770 | |
Ovarian Cancer First-Line Drug-Treated Patients (Zejula Target)3 | 46,448 | 46,448 | 46,448 | 46,448 | 36,444 | 36,444 | 36,444 | 36,444 | 39,823 | 39,823 | 39,823 | 39,823 | |
Core Operating Profit5 | 3,076.00 | 2,800.00 | 2,650.00 | 1,634.00 | 2,985.00 | 2,631.00 | 2,533.00 | 1,431.00 | 2,761.00 | 2,513.00 | 2,443.00 | 1,752.00 | |
Core Gross Profit | 6,847.00 | 6,511.00 | 5,928.00 | 6,183.00 | 6,488.00 | 6,000.00 | 5,790.00 | 5,778.00 | 6,091.00 | 6,007.00 | 5,630.00 | 5,889.00 | |
Core Cost of Sales | -2,040.00 | -1,898.00 | -1,701.00 | -2,435.00 | -2,059.00 | -1,986.00 | -1,726.00 | -2,339.00 | -1,921.00 | -1,877.00 | -1,733.00 | -2,163.00 | |
Core Selling, General & Administrative (SG&A) | -2,155.00 | -2,194.00 | -1,980.00 | -2,677.00 | -2,159.00 | -2,093.00 | -2,060.00 | -2,702.00 | -2,070.00 | -2,223.00 | -1,979.00 | -2,588.00 | |
Core Research & Development (R&D) | -1,874.00 | -1,721.00 | -1,493.00 | -2,117.00 | -1,552.00 | -1,522.00 | -1,377.00 | -1,821.00 | -1,428.00 | -1,415.00 | -1,359.00 | -1,784.00 | |
Royalty Income | 258.00 | 204.00 | 195.00 | 245.00 | 208.00 | 246.00 | 180.00 | 176.00 | 168.00 | 144.00 | 151.00 | 235.00 | |
Adjusting Item — Transaction-Related & ViiV Contingent Consideration Remeasurement4 | 349.00 | 491.00 | 279.00 | 266.00 | 319.00 | -88.00 | 10.00 | 418.00 | 361.00 | 398.00 | 704.00 | 455.00 | |
Adjusting Item — Intangible Asset Amortization | 220.00 | 195.00 | 190.00 | 197.00 | 198.00 | 194.00 | 219.00 | 198.00 | 415.00 | 193.00 | 196.00 | 184.00 | |
Adjusting Item — Intangible Asset Impairment | 33.00 | 1,895.00 | 172.00 | 228.00 | 112.00 | 476.00 | 64.00 | 196.00 | 17.00 | 47.00 | 54.00 | 249.00 | |
Adjusting Item — Major Restructuring Costs | 345.00 | 23.00 | 24.00 | 18.00 | 58.00 | 13.00 | 20.00 | 72.00 | 100.00 | 124.00 | 57.00 | 118.00 | |
Adjusting Item — Divestments, Significant Legal (Zantac) & Other Items | 2.00 | -285.00 | -308.00 | -175.00 | -295.00 | 13.00 | 4.00 | -149.00 | 1,679.00 | 105.00 | -58.00 | 173.00 | |
Core Profit Attributable to GSK Shareholders7 | 2,189.00 | 2,028.00 | 1,872.00 | 1,026.00 | 2,217.00 | 1,890.00 | 1,836.00 | 946.00 | 2,028.00 | 1,771.00 | 1,752.00 | 1,173.00 | |
Core Profit Before Taxation | 2,877.00 | 2,676.00 | 2,503.00 | 1,481.00 | 2,848.00 | 2,504.00 | 2,432.00 | 1,293.00 | 2,646.00 | 2,364.00 | 2,310.00 | 1,560.00 | |
Core Net Finance Expense | -197.00 | -121.00 | -143.00 | -150.00 | -132.00 | -125.00 | -101.00 | -138.00 | -114.00 | -148.00 | -132.00 | -191.00 | |
Core Taxation Charge | -490.00 | -457.00 | -458.00 | -256.00 | -455.00 | -439.00 | -434.00 | -174.00 | -461.00 | -423.00 | -404.00 | -235.00 | |
Core Effective Tax Rate(%) | 17.0% | 17.1% | 18.3% | 17.3% | 16.0% | 17.5% | 17.8% | 13.5% | 17.4% | 17.9% | 17.5% | 15.1% | |
Core Profit After Taxation (Consolidated) | 2,387.00 | 2,219.00 | 2,045.00 | 1,225.00 | 2,393.00 | 2,065.00 | 1,998.00 | 1,119.00 | 2,185.00 | 1,941.00 | 1,906.00 | 1,325.00 | |
Core Profit Attributable to Non-Controlling Interests (ViiV) | 198.00 | 191.00 | 173.00 | 199.00 | 176.00 | 175.00 | 162.00 | 173.00 | 157.00 | 170.00 | 154.00 | 152.00 | |
Core Earnings Per Share (Basic) | 54.60 | 50.50 | 46.50 | 25.50 | 55.00 | 46.50 | 44.90 | 23.20 | 49.70 | 43.40 | 43.10 | 28.90 | |
Other Intangible Assets Carrying Value (Excluding Goodwill) | 25,172.00 | 16,802.00 | 18,138.00 | 16,748.00 | 16,865.00 | 15,376.00 | 16,258.00 | 15,515.00 | 15,010.00 | 15,473.00 | 15,667.00 | 14,768.00 | |
Total Inventories by Manufacturing Stage | 6,300.00 | 6,282.00 | 6,157.00 | 5,924.00 | 6,118.00 | 6,072.00 | 6,000.00 | 5,669.00 | 5,918.00 | 5,859.00 | 5,702.00 | 5,498.00 | |
Contingent Consideration Liabilities — Total Fair Value2 | |||||||||||||
Contingent Consideration Liabilities — Non-Current | 5,311.00 | 5,405.00 | 5,278.00 | 5,385.00 | 5,547.00 | 5,442.00 | 5,854.00 | 6,108.00 | 6,020.00 | 6,043.00 | 5,981.00 | 5,609.00 | |
Contingent Consideration Liabilities — Current | 1,318.00 | 1,376.00 | 1,395.00 | 1,348.00 | 1,236.00 | 1,134.00 | 1,175.00 | 1,172.00 | 1,105.00 | 1,095.00 | 1,094.00 | 1,053.00 | |
Total Voting Rights (Issued Ordinary Shares Excluding Treasury)1 | |||||||||||||
Basic Weighted Average Ordinary Shares(M) | 4,009 | 4,014 | 4,023 | 4,019 | 4,034 | 4,063 | 4,088 | 4,081 | 4,080 | 4,079 | 4,069 | 4,056 | |
Net Debt4 | 20,739.00 | 15,132.00 | 15,613.00 | 14,453.00 | 14,444.00 | 13,735.00 | 13,947.00 | 13,095.00 | 12,847.00 | 13,960.00 | 14,961.00 | 15,040.00 | |
Cash & Cash Equivalents | 2,934.00 | 3,105.00 | 3,442.00 | 3,397.00 | 3,296.00 | 3,599.00 | 4,464.00 | 3,870.00 | 3,192.00 | 2,962.00 | 2,790.00 | 2,936.00 | |
Liquid Investments | 28.00 | 1.00 | 1.00 | 9.00 | 10.00 | 20.00 | 21.00 | 21.00 | 20.00 | 21.00 | 21.00 | 42.00 | |
Short-Term Borrowings & Current Lease Liabilities | 2,001.00 | 4,291.00 | 5,044.00 | 3,012.00 | 2,856.00 | 2,050.00 | 1,958.00 | 2,349.00 | 2,815.00 | 3,366.00 | 2,616.00 | 2,813.00 | |
Long-Term Borrowings & Non-Current Lease Liabilities | 21,700.00 | 13,947.00 | 14,012.00 | 14,708.00 | 14,894.00 | 15,304.00 | 16,474.00 | 14,637.00 | 13,244.00 | 13,577.00 | 15,156.00 | 15,205.00 | |
Free Cash Flow (GSK Reported Definition)8 | 2,078.00 | 1,994.00 | 815.00 | 960.00 | 1,246.00 | 1,126.00 | 697.00 | 924.00 | 1,322.00 | 328.00 | 289.00 | 2,095.00 | |
Net Cash Inflow from Operating Activities | 2,809.00 | 2,690.00 | 1,141.00 | 2,278.00 | 2,222.00 | 2,096.00 | 1,145.00 | 2,329.00 | 2,154.00 | 1,113.00 | 958.00 | 3,196.00 | |
Purchase of Property, Plant & Equipment | 374.00 | 328.00 | 221.00 | 573.00 | 311.00 | 256.00 | 208.00 | 544.00 | 305.00 | 302.00 | 248.00 | 486.00 | |
Proceeds from Sale of Property, Plant & Equipment | 3.00 | 3.00 | 27.00 | 13.00 | 5.00 | 5.00 | 1.00 | 61.00 | 1.00 | 2.00 | 1.00 | 7.00 | |
Purchase of Intangible Assets (Upfront & Milestone Payments) | 159.00 | 325.00 | 222.00 | 452.00 | 568.00 | 377.00 | 240.00 | 591.00 | 537.00 | 140.00 | 315.00 | 297.00 | |
Proceeds from Disposal of Intangible Assets | 1.00 | 293.00 | 62.00 | 3.00 | 36.00 | 76.00 | 5.00 | 98.00 | 1.00 | 27.00 | |||
Net Finance Costs Paid | 66.00 | 225.00 | 40.00 | 258.00 | 34.00 | 217.00 | 16.00 | 200.00 | 13.00 | 247.00 | 34.00 | 254.00 | |
Contingent Consideration Paid (Investing Cash Outflow) | 88.00 | 4.00 | 4.00 | 6.00 | 5.00 | 3.00 | 3.00 | 8.00 | 4.00 | 4.00 | 3.00 | 4.00 | |
Dividends Paid to Non-Controlling Interests (Pfizer & Shionogi in ViiV) | 102.00 | 137.00 | 115.00 | 99.00 | 122.00 | 58.00 | |||||||
U.S. Federal Prime Contract Obligations — GlaxoSmithKline (Monthly)3 | |||||||||||||
U.S. Federal Obligations to GSK — Dept. of Health & Human Services (CDC Vaccines)($M) | 27.6 | 9.15 | 2.99 | -0.10 | 8.08 | 20.9 | -4.07 | 0 | 11.0 | 25.7 | 21.8 | -0.03 | |
U.S. Federal Obligations to GSK — Department of Veterans Affairs (VA)($M) | 0 | -0.02 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.59 | 0.98 | 0 | |
U.S. Federal Obligations to GSK — Department of Defense (DoD / DHA)($M) | 0.05 | 0.02 | 0 | 0 | 0.03 | 0 | 0 | 0 | 0.06 | 0.04 | 1.55 | 0 | |
U.S. Dollar to British Pound Spot Exchange Rate (USD per £1.00 — FRED EXUSUK) | 1.34 | 1.33 | 1.33 | 1.34 | 1.35 | 1.36 | 1.29 | 1.27 | 1.32 | 1.27 | 1.27 | 1.27 | |
U.S. Personal Consumption Expenditures: Health Care (SAAR — BEA / FRED)3 | 3,858.70 | 3,790.30 | 3,699.90 | 3,667.00 | 3,614.90 | 3,529.80 | 3,464.70 | 3,417.80 | 3,358.20 | 3,288.20 | 3,244.40 | 3,159.40 | |
Consolidated IFRS Turnover (Revenue)16 | 8,887.00 | 8,409.00 | 7,629.00 | 8,618.00 | 8,547.00 | 7,986.00 | 7,516.00 | 8,117.00 | 8,012.00 | 7,884.00 | 7,363.00 | 8,052.00 | |
IFRS Cost of Sales | -2,390.00 | -2,266.00 | -1,875.00 | -2,657.00 | -2,258.00 | -2,165.00 | -1,937.00 | -2,559.00 | -2,397.00 | -2,122.00 | -1,970.00 | -2,418.00 | |
IFRS Gross Profit | 6,497.00 | 6,143.00 | 5,754.00 | 5,961.00 | 6,289.00 | 5,821.00 | 5,579.00 | 5,558.00 | 5,615.00 | 5,762.00 | 5,393.00 | 5,634.00 | |
IFRS Selling, General & Administration (SG&A) | -2,383.00 | -2,202.00 | -2,119.00 | -2,639.00 | -2,239.00 | -2,140.00 | -2,070.00 | -2,663.00 | -3,800.00 | -2,465.00 | -2,087.00 | -2,678.00 | |
IFRS Research & Development (R&D) | -1,983.00 | -3,466.00 | -1,692.00 | -2,350.00 | -1,689.00 | -2,024.00 | -1,462.00 | -2,031.00 | -1,459.00 | -1,477.00 | -1,434.00 | -2,047.00 | |
IFRS Royalty Income | 258.00 | 204.00 | 195.00 | 245.00 | 208.00 | 246.00 | 180.00 | 176.00 | 168.00 | 144.00 | 151.00 | 235.00 | |
IFRS Other Operating Income / (Expense) | -262.00 | -198.00 | 155.00 | -117.00 | 24.00 | 120.00 | -11.00 | -344.00 | -335.00 | -318.00 | -533.00 | -571.00 | |
IFRS Operating Profit | 2,127.00 | 481.00 | 2,293.00 | 1,100.00 | 2,593.00 | 2,023.00 | 2,216.00 | 696.00 | 189.00 | 1,646.00 | 1,490.00 | 573.00 | |
IFRS Finance Income | 29.00 | 58.00 | 22.00 | 39.00 | 26.00 | 50.00 | 54.00 | 34.00 | 32.00 | 24.00 | 32.00 | 29.00 | |
IFRS Finance Expense | -219.00 | -182.00 | -167.00 | -188.00 | -167.00 | -184.00 | -162.00 | -173.00 | -156.00 | -174.00 | -166.00 | -222.00 | |
IFRS Profit Before Taxation | 1,935.00 | 354.00 | 2,144.00 | 950.00 | 2,456.00 | 1,887.00 | 2,108.00 | 563.00 | 64.00 | 1,495.00 | 1,355.00 | 379.00 | |
IFRS Taxation Charge | -232.00 | 199.00 | -305.00 | -223.00 | -312.00 | -241.00 | -336.00 | -62.00 | 1.00 | -191.00 | -274.00 | 19.00 | |
IFRS Profit After Taxation (Consolidated) | 1,703.00 | 553.00 | 1,839.00 | 727.00 | 2,144.00 | 1,646.00 | 1,772.00 | 501.00 | 65.00 | 1,304.00 | 1,081.00 | 398.00 | |
IFRS Profit Attributable to Non-Controlling Interests | 160.00 | 118.00 | 102.00 | 91.00 | 131.00 | 203.00 | 148.00 | 87.00 | 123.00 | 131.00 | 35.00 | 48.00 | |
IFRS Profit Attributable to GSK Shareholders | 1,543.00 | 435.00 | 1,737.00 | 636.00 | 2,013.00 | 1,443.00 | 1,624.00 | 414.00 | -58.00 | 1,173.00 | 1,046.00 | 350.00 | |
IFRS Basic Earnings Per Share | 38.50 | 10.80 | 43.20 | 15.80 | 49.90 | 35.50 | 39.70 | 10.10 | -1.40 | 28.80 | 25.70 | 8.60 | |
IFRS Diluted Earnings Per Share | 37.90 | 10.70 | 42.60 | 15.60 | 49.10 | 35.10 | 39.30 | 10.00 | -1.40 | 28.50 | 25.40 | 8.50 | |
Consolidated IFRS Total Assets13 | 71,699.00 | 61,738.00 | 62,869.00 | 61,118.00 | 61,339.00 | 59,258.00 | 60,705.00 | 59,463.00 | 58,049.00 | 58,066.00 | 58,511.00 | 59,005.00 | |
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- GSK plc reports consolidated financial and commercial operating results under IFRS in British Pounds Sterling (£M and pence per share), with fiscal years ending December 31.
- Following the July 2022 demerger of Haleon (Consumer Healthcare), continuing commercial turnover is organized into Specialty Medicines (HIV, Respiratory/Immunology & Inflammation, Oncology), Vaccines, and General Medicines across the U.S., Europe, and International regions.
- ViiV Healthcare is GSK's global HIV specialist subsidiary (78.3% owned by GSK, 11.7% by Pfizer, and 10.0% by Shionogi); 100% of ViiV turnover is consolidated within Specialty Medicines — HIV, with Pfizer and Shionogi's share recognized in Non-Controlling Interests and Shionogi's royalty obligation carried as a Contingent Consideration Liability.
- GSK U.S. 401(k) Plan and Puerto Rico Thrift Plan figures are reported in exact U.S. Dollars ($) from audited Form 11-K filings; U.S. federal procurement obligations from USAspending.gov are reported in USD millions ($M).
- Every figure in this table is directly reported in SEC filings, official GSK Investor Relations / Sustainability disclosures, UK statutory filings, or U.S. government datasets; metrics are displayed only when the three most recent quarters or months (or two most recent fiscal years for annual-only disclosures) are continuously reported.
Không hiện vì thiếu các kỳ gần đây (34)
- Consumer Healthcare Segment (Haleon) — demerged in July 2022 and classified as discontinued operations; excluded from continuing Commercial Operations.
- U.S. Gross-to-Net (RAR) Channel Sub-Splits (Medicaid, Medicare Part D, Managed Care, 340B Chargebacks) — disclosed in Form 20-F narrative only as approximate rounded percentages rather than exact £M point series.
- Medicine Unit Doses / Prescription Volumes (Except Gavi Rotarix Supply) — GSK reports commercial medicines and vaccines strictly in £M turnover and CER % without commercial vial or prescription counts.
- Newly Launched Medicines with Fewer Than 3 Consecutive Quarters as of Q3 2026 — Blujepa (gepotidacin, launched Q1 2026 with Q1 and Q3 figures) and Jideytro (initial Q3 2026 launch figure).
- Discontinued / De-Materialized Legacy & Pandemic Products — Xevudy (sotrovimab), Pandemic Adjuvant Vaccines, Rukobia, Synflorix, Augmentin, Lamictal, and Avodart ceased standalone quarterly table disclosure prior to 2026.
- Specialty Medicines Turnover by Therapy Area, Brand & Region › Specialty Medicines Total Turnover › HIV Portfolio Total (ViiV Healthcare) › Long-Acting Injectable HIV Regimens (Treatment & PrEP) › Apretude (cabotegravir Long-Acting HIV PrEP) › Apretude (cabotegravir Long-Acting HIV PrEP) — Europe — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Specialty Medicines Turnover by Therapy Area, Brand & Region › Specialty Medicines Total Turnover › HIV Portfolio Total (ViiV Healthcare) › Rukobia (fostemsavir) › Rukobia (fostemsavir) — Constant Exchange Rate (CER) YoY Growth — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Specialty Medicines Turnover by Therapy Area, Brand & Region › Specialty Medicines Total Turnover › HIV Portfolio Total (ViiV Healthcare) › Rukobia (fostemsavir) › Rukobia (fostemsavir) — U.S. — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Specialty Medicines Turnover by Therapy Area, Brand & Region › Specialty Medicines Total Turnover › HIV Portfolio Total (ViiV Healthcare) › Rukobia (fostemsavir) › Rukobia (fostemsavir) — Europe — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Specialty Medicines Turnover by Therapy Area, Brand & Region › Specialty Medicines Total Turnover › HIV Portfolio Total (ViiV Healthcare) › Rukobia (fostemsavir) › Rukobia (fostemsavir) — International — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Specialty Medicines Turnover by Therapy Area, Brand & Region › Specialty Medicines Total Turnover › HIV Portfolio Total (ViiV Healthcare) › Rukobia (fostemsavir) — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Specialty Medicines Turnover by Therapy Area, Brand & Region › Specialty Medicines Total Turnover › Oncology Portfolio Total › Blenrep (belantamab mafodotin — BCMA ADC) › Blenrep (belantamab mafodotin — BCMA ADC) — Constant Exchange Rate (CER) YoY Growth — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Specialty Medicines Turnover by Therapy Area, Brand & Region › Specialty Medicines Total Turnover › Oncology Portfolio Total › Jideytro — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Specialty Medicines Turnover by Therapy Area, Brand & Region › Specialty Medicines Total Turnover › Pandemic Specialty (Xevudy / sotrovimab) — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Vaccines & General Medicines Turnover by Brand & Region › Vaccines Total Turnover › Arexvy (RSV Older Adults Vaccine) › Arexvy (RSV Older Adults Vaccine) — Constant Exchange Rate (CER) YoY Growth — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Vaccines & General Medicines Turnover by Brand & Region › Vaccines Total Turnover › Fluarix / FluLaval (Seasonal Influenza Vaccines) › Fluarix / FluLaval (Seasonal Influenza Vaccines) — Constant Exchange Rate (CER) YoY Growth — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Vaccines & General Medicines Turnover by Brand & Region › Vaccines Total Turnover › Fluarix / FluLaval (Seasonal Influenza Vaccines) › Fluarix / FluLaval (Seasonal Influenza Vaccines) — U.S. — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Vaccines & General Medicines Turnover by Brand & Region › Vaccines Total Turnover › Fluarix / FluLaval (Seasonal Influenza Vaccines) › Fluarix / FluLaval (Seasonal Influenza Vaccines) — Europe — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Vaccines & General Medicines Turnover by Brand & Region › Vaccines Total Turnover › Established / Paediatric & Adult Vaccines Total › Established / Paediatric & Adult Vaccines Total — Constant Exchange Rate (CER) YoY Growth — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Vaccines & General Medicines Turnover by Brand & Region › Vaccines Total Turnover › Established / Paediatric & Adult Vaccines Total › Synflorix (Pneumococcal Conjugate Vaccine) — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Vaccines & General Medicines Turnover by Brand & Region › Vaccines Total Turnover › Pandemic Adjuvant Vaccines — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Vaccines & General Medicines Turnover by Brand & Region › General Medicines Total Turnover › General Medicines Total Turnover — Constant Exchange Rate (CER) YoY Growth — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Vaccines & General Medicines Turnover by Brand & Region › General Medicines Total Turnover › General Medicines — Inhaled Respiratory Portfolio › Trelegy Ellipta (ICS/LAMA/LABA Single-Inhaler Triple Therapy) › Trelegy Ellipta (ICS/LAMA/LABA Single-Inhaler Triple Therapy) — Constant Exchange Rate (CER) YoY Growth — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Vaccines & General Medicines Turnover by Brand & Region › General Medicines Total Turnover › Other General Medicines (Anti-Infectives, CNS, Urology & Legacy Brands) › Blujepa (gepotidacin — Oral Uncomplicated UTI Antibiotic) — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Vaccines & General Medicines Turnover by Brand & Region › General Medicines Total Turnover › Other General Medicines (Anti-Infectives, CNS, Urology & Legacy Brands) › Augmentin (amoxicillin/clavulanate) — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Vaccines & General Medicines Turnover by Brand & Region › General Medicines Total Turnover › Other General Medicines (Anti-Infectives, CNS, Urology & Legacy Brands) › Lamictal (lamotrigine) — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Vaccines & General Medicines Turnover by Brand & Region › General Medicines Total Turnover › Other General Medicines (Anti-Infectives, CNS, Urology & Legacy Brands) › Avodart (dutasteride) — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- R&D Clinical Pipeline & Addressable Disease Epidemiology › Medicines & Vaccines in Clinical Development (Phase I–III / Registration) › Phase III / Registration Pipeline Assets › Phase III / Registration — HIV — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- R&D Clinical Pipeline & Addressable Disease Epidemiology › Medicines & Vaccines in Clinical Development (Phase I–III / Registration) › Phase II Pipeline Assets › Phase II — HIV — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- R&D Clinical Pipeline & Addressable Disease Epidemiology › Medicines & Vaccines in Clinical Development (Phase I–III / Registration) › Phase I Pipeline Assets › Phase I — Oncology — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- U.S. 401(k) & Puerto Rico Retirement Savings Plans (Form 11-K) › GSK U.S. 401(k) Plan — Net Assets Available for Benefits › GSK U.S. 401(k) Plan — Total Annual Contributions › GSK U.S. 401(k) Plan — Participant Rollover Contributions — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- U.S. 401(k) & Puerto Rico Retirement Savings Plans (Form 11-K) › GSK Puerto Rico Thrift Plan — Net Assets Available for Benefits › GSK Puerto Rico Thrift Plan — Participant Loans Receivable — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- U.S. 401(k) & Puerto Rico Retirement Savings Plans (Form 11-K) › GSK Puerto Rico Thrift Plan — Net Assets Available for Benefits › GSK Puerto Rico Thrift Plan — Total Annual Contributions › GSK Puerto Rico Thrift Plan — Participant Rollover Contributions — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
- Global Workforce, Defined Benefit Pensions, UK Pay Gap & Sustainability › Scope 1 Operational Carbon Emissions (Energy & Transport) › Mosquirix (RTS,S) Malaria Vaccine Doses Supplied — fewer than 3 consecutive latest periods (or 2 latest fiscal years) reported
Dữ liệu cập nhật 2026-11-07.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Commercial Turnover by Region & U.S. Gross-to-Net (RAR) Pricing
Specialty Medicines Turnover by Therapy Area, Brand & Region
Vaccines & General Medicines Turnover by Brand & Region
R&D Clinical Pipeline & Addressable Disease Epidemiology
- Medicines & Vaccines in Clinical Development (Phase I–III / Registration)8 kỳ
- Total Clinical Development Projects (Including Lifecycle Indications)18 kỳ
- Shingles Target Adult Population (Aged 50+)15 kỳ
- Shingles Immunocompromised / At-Risk Population (Aged 18–49)15 kỳ
- RSV Older Adults Target Population (Aged 65+)15 kỳ
- RSV Adults Target Population (Aged 60+)15 kỳ
- Seasonal Influenza Vaccine-Eligible Population (Aged 6 Months+)15 kỳ
- Meningitis Infant Target Cohort15 kỳ
- Meningitis Adolescent Target Cohort15 kỳ
- Pneumococcal Paediatric Target Cohort15 kỳ
- Pneumococcal Older Adult Target Population15 kỳ
- HIV Prevalent People Living with HIV (Key Tracked Markets)15 kỳ
- Chronic Hepatitis B (CHB) Prevalent Population (Bepirovirsen Target)15 kỳ
- Severe Asthma — Diagnosed Patient Population8 kỳ
- Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Prevalent Patients15 kỳ
- Hypereosinophilic Syndrome (HES) Diagnosed Patients8 kỳ
- Uncomplicated Urinary Tract Infection (uUTI) Annual Treated Episodes (Blujepa Target)15 kỳ
- Multiple Myeloma First-Line Drug-Treated Patients (Blenrep Target)15 kỳ
- Ovarian Cancer First-Line Drug-Treated Patients (Zejula Target)15 kỳ
Core (Adjusted) Operating Performance, Adjusting Items & Segments
Medicine Intangible Assets, R&D Commitments, Inventories & Contingent Liabilities
- Other Intangible Assets Carrying Value (Excluding Goodwill)39 kỳ
- Unrecorded Contractual Capital & Milestone Commitments6 kỳ
- Total Inventories by Manufacturing Stage39 kỳ
- Contingent Consideration Liabilities — Total Fair Value8 kỳ
- Provisions — Legal & Other Disputes (Including Zantac Settlements)6 kỳ
- Non-Current Operating Assets by Country — United Kingdom6 kỳ
Monthly Share Count / Voting Rights, Net Debt & Free Cash Flow
ViiV Healthcare Subsidiaries & Country-by-Country (CbCR) Hubs
- ViiV Healthcare Group (78.3% GSK / 11.7% Pfizer / 10.0% Shionogi) — Standalone IFRS Turnover7 kỳ
- ViiV Healthcare Limited (UK Co. 06876960 Holding Entity) — Dividend Income from Subsidiaries4 kỳ
- ViiV Healthcare UK Limited (UK Co. 06990358 Operating Entity) — Statutory Turnover8 kỳ
- Global CbCR Consolidated Total — Year-End Full-Time Equivalent (FTE) Employees2 kỳ
U.S. 401(k) & Puerto Rico Retirement Savings Plans (Form 11-K)
Global Workforce, Defined Benefit Pensions, UK Pay Gap & Sustainability
- Year-End Permanent Employees — Total Global Workforce4 kỳ
- Full-Year Average Employees (Including Temporary Staff)7 kỳ
- UK Defined Benefit Pension Schemes — Fair Value of Plan Assets5 kỳ
- GlaxoSmithKline Services Unlimited (UK) — Median Hourly Gender Pay Gap (%)9 kỳ
- Scope 1 Operational Carbon Emissions (Energy & Transport)4 kỳ
External U.S. Federal Vaccine/Rx Contracts & Macro Benchmarks
Consolidated IFRS Financial Statements
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của GSK
- GSK Form 6-K Results (FY2026Q3, filed 2026-10-28) ↗
- GSK Epidemiology Report (FY2026Q3, Excel) ↗
- GSK Epidemiology Report (FY2025Q4, Excel) ↗
- GSK Form 6-K Results (FY2025Q4, filed 2026-02-04) ↗
- GSK Form 20-F (FY2025, Inline XBRL) ↗
- FRED EXUSUK — U.S. Dollars to U.K. Pound Sterling Spot Rate ↗
- GSK Form 20-F Annual Report (FY2025) ↗
- GSK Monthly Form 6-K Total Voting Rights Notifications (FCA DTR 5.6.1R) ↗
- UK Companies House Statutory Accounts — ViiV Healthcare Limited (06876960) (31 December 2025) ↗
- UK Companies House Statutory Accounts — ViiV Healthcare UK Limited (06990358) (31 December 2025) ↗
- GSK Country-by-Country Report (2025) ↗
- GSK 401(k) Plan Form 11-K (FY2025) ↗
See a number that looks wrong?